Rankings
▼
Calendar
MESO Q3 2024 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
-35.2% YoY
Gross Profit
-$10M
-762.3% margin
Operating Income
-$22M
-1750.7% margin
Net Income
-$28M
-2204.3% margin
EPS (Diluted)
$-0.25
QoQ Revenue Growth
-25.8%
Cash Flow
Operating Cash Flow
$0
Free Cash Flow
-$41,000
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$669M
Total Liabilities
$189M
Stockholders' Equity
$480M
Cash & Equivalents
$63M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1M
$2M
-35.2%
Gross Profit
-$10M
-$11M
+15.8%
Operating Income
-$22M
-$14M
-52.2%
Net Income
-$28M
-$19M
-49.0%
← FY 2024
All Quarters
Q4 2024 →